Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients With X-Linked Hypophosphatemia - Takeaways - MDSpire

Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients With X-Linked Hypophosphatemia

  • By

  • Dalal S Ali

  • Reza D Mirza

  • Salma Hussein

  • Farah Alsarraf

  • R Todd Alexander

  • Hajar Abu Alrob

  • Natasha M Appelman-Dijkstra

  • Martin Biosse-Duplan

  • Maria Luisa Brandi

  • Thomas O Carpenter

  • Catherine Chaussain

  • Karel Dandurand

  • Guido Filler

  • Pablo Florenzano

  • Seiji Fukumoto

  • Corinna Grasemann

  • Erik A Imel

  • Suzanne M Jan de Beur

  • Emmett Morgante

  • Leanne M Ward

  • Aliya A Khan

  • Gordon Guyatt

  • January 9, 2025

  • 0 min

Share

  • 1

    Burosumab likely prevents lower limb deformity and improves physical health quality of life in children with X-linked hypophosphatemia.

  • 2

    Burosumab may increase height and reduce symptoms related to chronic hypophosphatemia, though evidence certainty is low.

  • 3

    Burosumab probably increases treatment-emergent adverse events and may lead to a higher incidence of dental abscesses.

  • 4

    Conventional therapy's impact on final height compared to no treatment has very low certainty evidence.

  • 5

    Further research is necessary to understand the long-term effects of medical therapy in children with X-linked hypophosphatemia.

Original Source(s)

Related Content